US Supreme Court overturns Purdue Pharma’s $6bn opioid settlement
The US Supreme Court invalidated Purdue Pharma's $6 billion opioid settlement, which would have funded epidemic relief and protected the Sackler family from lawsuits. The 5-4 ruling introduces uncertainty for Purdue and disrupts the use of non-consensual third-party releases in bankruptcy settlements, raising the potential for Congress to intervene.
Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Register here.
Join us for BizNews' first investment-focused conference on Thursday, 12 September, in Hermanus, featuring top experts like Frans Cronje, Piet Viljoen, and more. Get insights on electricity and exploiting SA's gas bounty from new and familiar faces. Register here.
By Jonathan Randles and Greg Stohr
The US Supreme Court tossed Purdue Pharma LP's $6 billion opioid settlement, nixing a deal that would have funded opioid epidemic relief efforts in exchange for protecting the company's billionaire owners from lawsuits alleging they helped fuel the addiction crisis.
___STEADY_PAYWALL___